|Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer|
P Lewis, P Marsden, T Gee, T Nunan, M Malsey, S Griffin, J Dussek
The Lancet 344 (8932), 1265-1266, 1994
|Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis.|
C McDaid, S Griffin, H Weatherly, K Duree, M Van der Burgt, S Van Hout, ...
Health technology assessment (Winchester, England) 13 (4), iii-iv, xi, 2009
|A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit …|
S King, S Griffin, Z Hodges, H Weatherly, C Asseburg, G Richardson, ...
Health Technology Assessment (Winchester, England) 10 (23), iii-146, 2006
|A systematic review of continuous positive airway pressure for obstructive sleep apnoea–hypopnoea syndrome|
C McDaid, KH Durée, SC Griffin, HLA Weatherly, JR Stradling, ...
Sleep medicine reviews 13 (6), 427-436, 2009
|Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority …|
AM Brunt, JS Haviland, DA Wheatley, MA Sydenham, A Alhasso, ...
The Lancet 395 (10237), 1613-1626, 2020
|Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial|
A McMillan, DJ Bratton, R Faria, M Laskawiec-Szkonter, S Griffin, ...
The Lancet Respiratory Medicine 2 (10), 804-812, 2014
|Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study|
SC Griffin, JA Barber, A Manca, MJ Sculpher, SG Thompson, MJ Buxton, ...
Bmj 334 (7594), 624, 2007
|Using cost-effectiveness analysis to address health equity concerns|
R Cookson, AJ Mirelman, S Griffin, M Asaria, B Dawkins, OF Norheim, ...
Value in Health 20 (2), 206-212, 2017
|Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development|
K Claxton, S Palmer, L Longworth, L Bojke, S Griffin, C McKenna, ...
NIHR Health Technology Assessment Programme, 2012
|Dangerous omissions: the consequences of ignoring decision uncertainty|
SC Griffin, KP Claxton, SJ Palmer, MJ Sculpher
Health economics 20 (2), 212-224, 2011
|Distributional cost-effectiveness analysis: a tutorial|
M Asaria, S Griffin, R Cookson
Medical Decision Making 36 (1), 8-19, 2016
|Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and …|
L Jones, S Griffin, S Palmer, C Main, V Orton, M Sculpher, C Sudlow, ...
Health Technology Assessment (Winchester, England) 8 (38), iii-196, 2004
|Distributional cost‐effectiveness analysis of health care programmes–a methodological case study of the UK bowel cancer screening programme|
M Asaria, S Griffin, R Cookson, S Whyte, P Tappenden
Health economics 24 (6), 742-754, 2015
|Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic …|
C Main, S Palmer, S Griffin, L Jones, V Orton, M Sculpher, R Henderson, ...
Health technology assessment (Winchester, England) 8 (40), iii-141, 2004
|Probabilistic analysis and computationally expensive models: necessary and required?|
S Griffin, K Claxton, N Hawkins, M Sculpher
Value in Health 9 (4), 244-252, 2006
|The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation|
D Farrar, M Simmonds, S Griffin, A Duarte, DA Lawlor, M Sculpher, ...
Health technology assessment, 1-348, 2016
|Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic …|
C Main, L Bojke, S Griffin, G Norman, M Barbieri, L Mather, D Stark, ...
Health technology assessment (Winchester, England) 10 (9), 1-132. iii, 2006
|Exploring the research decision space: the expected value of information for sequential research designs|
S Griffin, NJ Welton, K Claxton
Medical Decision Making 30 (2), 155-162, 2010
|Alitretinoin for severe chronic hand eczema|
M Rodgers, S Griffin, M Paulden, R Slack, S Duffy, JR Ingram, ...
Pharmacoeconomics 28 (5), 351-362, 2010
|Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.|
J Burch, S Griffin, C McKenna, S Walker, J Paton, K Wright, N Woolacott
Pharmacoeconomics 30 (11), 991-1004, 2012